睿知中国医院研究地图
候选清单

即将招募肺癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06594874,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 4

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(4 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Previous or current treatment with other KRAS G12C inhibitors

    排除标准第 2 条

    Local radiotherapy within 2 weeks prior to the first dose of study drug, more than 30% of bone marrow irradiation or large-area radiotherapy within 4 weeks before the first dose of study drug.

    排除标准第 4 条

    Presence of Grade ≥ 2 toxicities due to prior anti-tumor therapy.

    排除标准第 9 条

  3. Must have an ECOG performance status of 0 or 1.

    入选标准第 3 条

  4. At least one measurable lesion in accordance with RECIST 1.1

    入选标准第 2 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能;试验排除的其他疾病;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06594874,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Men or women greater than or equal to 18 years
  2. At least one measurable lesion in accordance with RECIST 1.1
  3. Must have an ECOG performance status of 0 or 1.
  4. Histologically or cytologically confirmed NSCLC with Stage IIIB-IIIC or Stage IV disease, not suitable for curative intent radical surgery or radiation therapy.
  5. Documentation of the presence of a KRAS G12C mutation
  6. Must provide tumor tissue sample
  7. No history of systemic anticancer therapy in metastatic/non-curable settings
  8. Estimated life expectancy ≥12 weeks.
  9. Reproductive-age women agree to use adequate contraception and cannot breastfeed while participating in this study and for a period of 6 months after the last dose.
  10. Females must have the evidence of non-childbearing potential; Likewise, men also consent to use adequate contraceptive method within the same time limit.
  11. Signed and dated Informed Consent Form.
  12. The subjects are able to comply with the process of the protocol.

排除标准:Exclusion Criteria:

  1. Treatment with any of the following:
  2. Previous or current treatment with other KRAS G12C inhibitors
  3. Any cytotoxic chemotherapy, anticancer Chinese medicine and targeted small molecule inhibitors within 14 days of the first dose of study treatment; Any investigational agents and large molecule antibodies within 28 days of the first dose of study treatment.
  4. Local radiotherapy within 2 weeks prior to the first dose of study drug, more than 30% of bone marrow irradiation or large-area radiotherapy within 4 weeks before the first dose of study drug.
  5. Major surgery (including craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks of the first dose
  6. Active brain metastases.
  7. Patients with uncontrolled pleural, ascites or pericardial effusion
  8. Spinal cord compression
  9. Presence of Grade ≥ 2 toxicities due to prior anti-tumor therapy.
  10. Subjects with tumors known to harbor molecular alterations for which targeted therapy is locally approved, except for KRAS G12C.
  11. History of other primary malignancies.
  12. Inadequate bone marrow reserve or organ functions.
  13. Abnormal cardiac examination results.
  14. Severe, uncontrolled or active cardiovascular disorders.
  15. Diabetes ketoacidosis or hyperglycemia hyperosmolality
  16. Uncontrolled hypertension.
  17. Severe bleeding symptoms or bleeding tendencies.
  18. Severe arteriovenous thrombosis occurred
  19. Serious infection.
  20. Continuous use of glucocorticoids
  21. Active infectious diseases.
  22. Refractory nausea, vomiting, or chronic gastrointestinal diseases, or inability to swallow oral medications
  23. Hepatic encephalopathy, hepatorenal syndrome, or ≥ Child Pugh B-grade cirrhosis.
  24. Interstitial lung disease (ILD).
  25. Serious neurological or mental disorders.
  26. Active autoimmune diseases

引自 ClinicalTrials.gov, NCT06594874, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06594874,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06594874